SCHEMBL6719161

SCHEMBL6719161

Cc1ccccc1NC(=O)C(c1ccccc1)N(S)C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CYP1A2 P05177 1/20 0.52
POLB P06746 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
TP53 P04637 1/20 0.51
RXFP1 Q9HBX9 4/20 0.51
GAA P10253 1/20 0.50
KDM4E B2RXH2 2/20 0.49
GRIK1 P39086 2/20 0.48
MAPT P10636 4/20 0.47
HTT P42858 2/20 0.47
RAB9A P51151 2/20 0.47
KDR P35968 1/20 0.47
LMNA P02545 2/20 0.46
DDX3X O00571 1/20 0.45
TACR1 P25103 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715571 0.86 KDM4E (0.50) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL6726997 0.82 MAPT (0.50) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL6715503 0.82 POLB (0.44) MEN1KMT2AALDH1A1CYP1A2POLB
SCHEMBL6713823 0.81 IMPDH2 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL6718048 0.81 KLK7 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL6719158 0.80 ULK1 (0.61) MEN1KMT2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL17079632 0.79 DDX3X (0.73) MEN1KMT2AALDH1A1RXFP1GAA
SCHEMBL6715754 0.78 MAPT (0.46) MEN1KMT2AALDH1A1POLBTP53
SCHEMBL6716817 0.77 POLB (0.42) MEN1KMT2AALDH1A1POLBCYP3A4
SCHEMBL6719554 0.77 NPY5R (0.50) MEN1KMT2AALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 MEN1 2822/4885KMT2A 1656/4885ALDH1A1 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.